MRM Proteomics is excited to announce a strategic co-marketing and collaboration agreement with Newomics Inc., a leader in cutting-edge microfluidic separation and ionization technologies for mass spectrometry. This partnership represents a powerful synergy between two companies at the forefront of precision multiomics, with a shared mission to accelerate the development and deployment of advanced analytical solutions for clinical research, biomarker discovery, and drug development.

MRM Proteomics brings over 15 years of experience in the absolute quantitation of proteins and metabolites in complex biological samples using the MRM technology, offering standardized, reproducible, and validated workflows to researchers and industry partners worldwide. Newomics complements this expertise with its proprietary multispray technology with multinozzle M3 emitter and MEA chip, which enables significant improvements in sensitivity, robustness, and throughput for LC-MS-based analyses. Their innovations have become increasingly valuable in applications requiring low sample volumes, high data quality, and scalable performance—especially in clinical proteomics, metabolomics, and single-cell analysis.

Through this collaboration, the two companies will work closely to integrate their platforms, develop co-branded applications, and jointly promote novel solutions that combine MRM Proteomics’ rigorously validated assays, kits and analytical services with Newomics’ high-performance separation and ionization tools. This includes collaborative R&D, demonstration projects, and marketing initiatives targeting academic institutions, CROs, diagnostic developers, and biopharmaceutical companies across North America, Europe, and beyond.

“We are excited to partner with Newomics, whose technology perfectly complements our goal of delivering the highest standards in clinical omics through our PeptiQuant and recently developed SysQuan technology,” said Paula Jahshan, CEO of MRM Proteomics. “Together, we aim to enable our clients and collaborators to achieve deeper biological insights and faster translational outcomes by providing assays and kits for highly multiplexed, sensitive, reproducible and robust absolute quantitation for both proteins and metabolites.”

“We are excited to collaborate further with MRM Proteomics, a company at the forefront of quantitative multiomics,” said Daojing Wang, Ph.D., Founder and CEO of Newomics. “Our UniESI platform with M3 emitters and MEA chips, combined with their assays and kits, will enable accurate quantitation of peptides, proteins, and metabolites for biomarker discovery and drug development. We will showcase advances in quantitative proteomics using our joint platform at the upcoming ASMS 2025 in Baltimore.”

This agreement reflects the shared vision of both companies in advancing precision medicine by breaking down barriers to high-quality multiomics data. By combining Newomics’ engineering innovations with MRM Proteomics’ scientific and clinical expertise, the collaboration promises to empower laboratories with tools that are not only powerful and scalable but also ready for regulatory and clinical use.

Stay tuned for more updates as MRM Proteomics and Newomics roll out joint offerings, technical resources, and live demonstrations in the months ahead.